Altretamine for the treatment of metastatic renal cell carcinoma

A Hoosier Oncology Group trial

Robin T. Zon, John Mcclean, Douglas Helman, Rafat Ansari, Joel Picus, Alan Sandler, Stephen D. Williams, Patrick Loehrer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.

Original languageEnglish
Pages (from-to)229-231
Number of pages3
JournalInvestigational New Drugs
Volume19
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Altretamine
Renal Cell Carcinoma
Gait
Nausea
Vomiting
Therapeutics

Keywords

  • Altretamine
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Altretamine for the treatment of metastatic renal cell carcinoma : A Hoosier Oncology Group trial. / Zon, Robin T.; Mcclean, John; Helman, Douglas; Ansari, Rafat; Picus, Joel; Sandler, Alan; Williams, Stephen D.; Loehrer, Patrick.

In: Investigational New Drugs, Vol. 19, No. 3, 2001, p. 229-231.

Research output: Contribution to journalArticle

Zon, RT, Mcclean, J, Helman, D, Ansari, R, Picus, J, Sandler, A, Williams, SD & Loehrer, P 2001, 'Altretamine for the treatment of metastatic renal cell carcinoma: A Hoosier Oncology Group trial', Investigational New Drugs, vol. 19, no. 3, pp. 229-231. https://doi.org/10.1023/A:1010620601431
Zon, Robin T. ; Mcclean, John ; Helman, Douglas ; Ansari, Rafat ; Picus, Joel ; Sandler, Alan ; Williams, Stephen D. ; Loehrer, Patrick. / Altretamine for the treatment of metastatic renal cell carcinoma : A Hoosier Oncology Group trial. In: Investigational New Drugs. 2001 ; Vol. 19, No. 3. pp. 229-231.
@article{2366a9a5efc8443a9884c78789b17314,
title = "Altretamine for the treatment of metastatic renal cell carcinoma: A Hoosier Oncology Group trial",
abstract = "Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.",
keywords = "Altretamine, Renal cell carcinoma",
author = "Zon, {Robin T.} and John Mcclean and Douglas Helman and Rafat Ansari and Joel Picus and Alan Sandler and Williams, {Stephen D.} and Patrick Loehrer",
year = "2001",
doi = "10.1023/A:1010620601431",
language = "English",
volume = "19",
pages = "229--231",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Altretamine for the treatment of metastatic renal cell carcinoma

T2 - A Hoosier Oncology Group trial

AU - Zon, Robin T.

AU - Mcclean, John

AU - Helman, Douglas

AU - Ansari, Rafat

AU - Picus, Joel

AU - Sandler, Alan

AU - Williams, Stephen D.

AU - Loehrer, Patrick

PY - 2001

Y1 - 2001

N2 - Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.

AB - Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.

KW - Altretamine

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0034845091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034845091&partnerID=8YFLogxK

U2 - 10.1023/A:1010620601431

DO - 10.1023/A:1010620601431

M3 - Article

VL - 19

SP - 229

EP - 231

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -